Market closed
Celldex/$CLDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celldex
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Ticker
$CLDX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
186
Website
Celldex Metrics
BasicAdvanced
$1.3B
-
-$2.45
1.76
-
Price and volume
Market cap
$1.3B
Beta
1.76
52-week high
$48.37
52-week low
$18.61
Average daily volume
772K
Financial strength
Current ratio
18.915
Quick ratio
18.379
Long term debt to equity
0.316
Total debt to equity
0.51
Management effectiveness
Return on assets (TTM)
-19.38%
Return on equity (TTM)
-26.84%
Valuation
Price to revenue (TTM)
179.426
Price to book
1.74
Price to tangible book (TTM)
1.84
Price to free cash flow (TTM)
-7.887
Growth
Revenue change (TTM)
1.99%
Earnings per share change (TTM)
-16.02%
3-year revenue growth (CAGR)
14.71%
3-year earnings per share growth (CAGR)
14.23%
What the Analysts think about Celldex
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Celldex stock.
Celldex Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Celldex Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Celldex News
AllArticlesVideos
Celldex Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire·1 week ago
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
GlobeNewsWire·1 week ago
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Celldex stock?
Celldex (CLDX) has a market cap of $1.3B as of March 12, 2025.
What is the P/E ratio for Celldex stock?
The price to earnings (P/E) ratio for Celldex (CLDX) stock is 0 as of March 12, 2025.
Does Celldex stock pay dividends?
No, Celldex (CLDX) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Celldex dividend payment date?
Celldex (CLDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Celldex?
Celldex (CLDX) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.